Nanomedicine: A pharma perspective

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 7, Issue 2, 2015, Pages 125-130

  Brown, Peter D ^a   Patel, Piyush R ^a  

^a TEVA PHARMACEUTICALS   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING;

ACADEMIC LABORATORY; COMMERCIAL-SCALE PRODUCTION; INNOVATIVE RESEARCH; LIPOSOMAL FORMULATION; PHARMACEUTICAL COMPANY; TECHNICAL CHALLENGES; THERAPEUTIC ACTIVITY; THERAPEUTIC INDEX;

MEDICAL NANOTECHNOLOGY;

DOXORUBICIN; LIPOSOME; NANOPARTICLE; DRUG;

ARTICLE; DRUG ACCUMULATION; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; ENHANCED PERMEABILITY AND RETENTION; NANOMEDICINE; NANOTECHNOLOGY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; CHEMISTRY; HUMAN; PROCEDURES;

HUMANS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS;

EID: 84921454131     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1288     Document Type: Article

References (31)

1. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211-1217.
2. ®-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160:117-134.
3. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
4. Waite CL, Roth CM. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng 2012, 40:21-41.
5. Vaage J, Barberá-Guillem E, Abra R, Huang A, Working P. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994, 73:1478-1484.
6. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54:987-992.
7. Working PK, Newman MS, Sullivan T, Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J Pharmacol Exp Ther 1999, 289:1128-1133.
8. Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst 2004, 96:1500-1509.
9. Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004, 95:1-8.
10. Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 2012, 107:588-591.
11. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25:3892-3901.
12. O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013, 31:676-683.
13. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001, 19:1444-1454.
14. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996, 14:2353-2364.
15. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19:3312-3322.
16. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM169203.pdf. (Accessed March 9, 2014).
17. Jiang W, Lionberger R, Yu LX. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis 2011, 3:333-344.
18. Sosnik A, Carcaboso AM, Chiappetta DA. Polymeric nanocarriers: new endeavours for the optimization of the technological aspects of drugs. Recent Pat Biomed Eng 2008, 1:43-59.
19. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011, 8:2101-2141.
20. Chang SS. Monoclonal antibodies and prostate-specific membrane antigen. Curr Opin Investig Drugs 2004, 5:611-615.
21. Summa J, LoRusso PM, Eisenberg P, Hrkrach J, Schnipper E, Von Hoff D. Abstract LB-452: a phase I, open label, safety, pharmacokinetic and pharmacodynamic dose escalation study of BIND-014 given by IV infusion to patients with advanced or metastatic cancer. Cancer Res 2012, 72:LB-452.
22. Miller K, Eldar-Boock A, Polyak D, Segal E, Benayoun L, Shaked Y, Satchi-Fainaro R. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm 2011, 8:1052-1062.
23. Caruthers SD, Winter PM, Wickline SA, Lanza GM, Keupp J. MR molecular imaging of angiogenesis using targeted perfluorocarbon nanoparticles. Medicamundi 2010, 54:5-13.
24. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001, 7:243-254.
25. http://investors.merrimackpharma.com/releasedetail.cfm?ReleaseID=844390. (Accessed June 26, 2014).
26. Ramanathan RR, Korn RL, Sachdev JC, Fetterly GJ, Marceau K, Marsh V, Neil JM, Newbold RG, Raghunand N, Prey J, et al. Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI) [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 5-9 April, 2014. Philadelphia, PA: AACR; 2014, Abstract nr CT224.
27. http://investor.celsion.com/releasedetail.cfm?ReleaseID=821197. (Accessed June 26, 2014).
28. Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, Harvie P, Bermudes D, Mayer L. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009, 33:129-139.
29. Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 2014, 123:3239-3246.
30. Markovsky E, Baabur-Cohen H, Satchi-Fainaro R. Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs. J Control Release 2014, 187:145-157.
31. Nehoff H, Parayath NN, Domanovitch L, Taurin S, Greish K. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int J Nanomedicine 2014, 9:2539-2555.